BridgeBio Pharma, Inc. BBIO
79.43 USD +1.50 (+1.92%)
Nov 10, 2026, 12:27 PM EST
76.60 Day range 79.83
62.81 52-week range 90.17
- YTD
- +3.84%
- 1 year
- +26.46%
News
globenewswire.com BridgeBio to Present New Acoramidis Data on Heart Failure Events in ATTR-CM at the American Heart Association Scientific Sessions 2026 PALO ALTO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on…
benzinga.com Canaccord Genuity Maintains Buy on BridgeBio Pharma, Raises Price Target to $108 Canaccord Genuity analyst Whitney Ijem maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $106 to $108.
benzinga.com TD Cowen Maintains Buy on BridgeBio Pharma, Lowers Price Target to $100 TD Cowen analyst Tyler Van Buren maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and lowers the price target from $110 to $100.
benzinga.com Morgan Stanley Maintains Overweight on BridgeBio Pharma, Raises Price Target to $88 Morgan Stanley analyst Sean Laaman maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $87 to $88.
benzinga.com BridgeBio Pharma Q3 2026 Earnings Call Transcript BridgeBio Pharma (NASDAQ:BBIO) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com Morgan Stanley Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $87 Morgan Stanley analyst Sean Laaman maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and lowers the price target from $97 to $87.- benzinga.com Citigroup Maintains Neutral on BridgeBio Pharma, Lowers Price Target to $91 Citigroup analyst Eric Joseph maintains BridgeBio Pharma (NASDAQ:BBIO) with a Neutral and lowers the price target from $94 to $91.
benzinga.com Piper Sandler Maintains Overweight on BridgeBio Pharma, Raises Price Target to $120 Piper Sandler analyst Biren Amin maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $115 to $120.- benzinga.com Reported Sunday, BridgeBio’s Encaleret Raises Bone Turnover, With 100% Of Phase 3 CALIBRATE Participants Reporting Improvement In At Least One ADH1 Symptom Versus 46% On Standard Of Care - Encaleret administration increased bone turnover, based on its action to recover endogenous PTH secretion in patients with ADH1- 100% of participants who received encaleret reported improvements in…
benzinga.com Reported Sunday, BridgeBio Presents Acoramidis Data At HFSA 2026 Showing 18% Lower Composite Risk Versus Tafamidis In Real-World Study Of 2,684 ATTR-CM Patients And Mortality Rising After Cardiovascular Hospitalizations - In an independent, propensity score-matched analysis of 2,684 individuals living with ATTR-CM from Epic COSMOS, the largest U.S. electronic health record database, acoramidis was associated with a…- benzinga.com Barclays Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $156 Barclays analyst Eliana Merle maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and lowers the price target from $157 to $156.
benzinga.com BridgeBio Pharma Receives FDA Acceptance For Filing Its New Drug Application With Priority Review For Oral Infigratinib To Treat Achondroplasia BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today…- benzinga.com Bridgebio Presents New Exploratory Cardiac Data From 12-Month Interim Analysis Of FORTIFY, Phase 3 Clinical Trial Of Oral BBP-418 In Individuals With Limb-Girdle Muscular Dystrophy Type 2I/R9, At 31st Annual Congress Of The World Muscle Society In Hiroshima - In exploratory analyses at Month 12, among individuals with LGMD2I/R9 (FKRP-related) with elevated HS troponin I at baseline, 100% treated with BBP-418 returned to the normal range by Month 12…
- benzinga.com HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $120 price target.
benzinga.com BridgeBio Dwarfism Data Shows Broad Health Benefits Beyond Height Gain BridgeBio Pharma shares 52-week data on oral infigratinib for achondroplasia, showing improvements in sleep apnea, otitis media, and BMI.
benzinga.com BridgeBio's Oral Infigratinib Shows Reduced Sleep Apnea And Ear Infection Rates Beyond Growth Benefits In Phase 3 PROPEL 3 Trial At 52 Weeks - Treatment with oral infigratinib for 52 weeks in PROPEL 3 resulted in favorable trends against placebo in clinically meaningful exploratory endpoints including sleep apnea and otitis media…- benzinga.com HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $120 price target.
- benzinga.com Mizuho Maintains Outperform on BridgeBio Pharma, Raises Price Target to $110 Mizuho analyst Salim Syed maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and raises the price target from $96 to $110.
benzinga.com Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President Trump secures drug pricing deals with nine pharma companies as Kennedy reveals intense pressure from the President to deliver.- benzinga.com Trump Administration Reaches New Drug Pricing Agreement With Nine Pharma Firms https://www.whitehouse.gov/fact-sheets/2026/08/fact-sheet-president-donald-j-trump-announces-deal-with-nine-additional-pharmaceutical-manufacturers-to-lower-drug-prices-for-americans/
- benzinga.com Reported Earlier, BridgeBio Reports New Data Suggesting Attruby Could Help Reverse Some Heart Damage BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, presented new
benzinga.com BridgeBio Pharma Doses First Patient In ASCEND-ATTR Trial To Evaluate Effects Of Acoramidis To Enhance Cardiac Structure, Function, And Amyloid Burden In Individuals With Transthyretin Amyloid Cardiomyopathy BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today- benzinga.com BridgeBio Pharma To Present Two Oral Presentations, Three Posters On New Acoramidis Data In Individuals With Transthyretin Amyloid Cardiomyopathy At European Society Of Cardiology Congress 2026 BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that two oral presentations and
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…- benzinga.com BridgeBio Pharma Launches Secondary Public Offering Of 5M Shares Of Common Stock By Selling Stockholder KKR Genetic Disorder L.P BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today the launch of a…
- benzinga.com Truist Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $107 Truist Securities analyst Danielle Brill maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $102 to $107.
- benzinga.com Canaccord Genuity Maintains Buy on BridgeBio Pharma, Raises Price Target to $106 Canaccord Genuity analyst Whitney Ijem maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $104 to $106.
- benzinga.com JP Morgan Maintains Overweight on BridgeBio Pharma, Raises Price Target to $111 JP Morgan analyst Anupam Rama maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $100 to $111.
- benzinga.com B of A Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $104 B of A Securities analyst Geoff Meacham maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $101 to $104.
- benzinga.com TD Cowen Maintains Buy on BridgeBio Pharma, Raises Price Target to $110 TD Cowen analyst Tyler Van Buren maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $95 to $110.
- benzinga.com Morgan Stanley Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $97 Morgan Stanley analyst Sean Laaman maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and lowers the price target from $98 to $97.
- benzinga.com Piper Sandler Maintains Overweight on BridgeBio Pharma, Raises Price Target to $115 Piper Sandler analyst Biren Amin maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $111 to $115.
- benzinga.com Wells Fargo Maintains Overweight on BridgeBio Pharma, Raises Price Target to $102 Wells Fargo analyst Derek Archila maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $98 to $102.
benzinga.com BridgeBio Pharma Q2 EPS $(0.78) Misses $(0.59) Estimate, Sales $243.676M Beat $218.743M Estimate BridgeBio Pharma (NASDAQ:BBIO) reported quarterly losses of $(0.78) per share which missed the analyst consensus estimate of $(0.59) by 32.2 percent. This is a 17.89 percent increase over losses of…
benzinga.com Earnings Volatility Watch: Applied Materials and 10 Other Stocks Could See Double-Digit Moves This Week Applied Materials, Coherent, CoreWeave and eight other names carry double-digit implied earnings moves in the second week of August. Here is what to watch.- benzinga.com BridgeBio Pharma Announces FDA Accepts For Filing Its New Drug Application For Encaleret To Treat Autosomal Dominant Hypocalcemia Type 1 BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced
- benzinga.com Citigroup Maintains Neutral on BridgeBio Pharma, Raises Price Target to $93 Citigroup analyst Eric Joseph maintains BridgeBio Pharma (NASDAQ:BBIO) with a Neutral and raises the price target from $82 to $93.
benzinga.com Keysight To Rally Over 24%? Here Are 10 Top Analyst Forecasts For Monday Wall Street analysts change outlook on top names. Complete view of analyst rating changes including upgrades/downgrades. See analyst ratings page.- benzinga.com HC Wainwright & Co. Maintains Buy on BridgeBio Pharma, Raises Price Target to $120 HC Wainwright & Co. analyst Raghuram Selvaraju maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $110 to $120.
benzinga.com Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain Ionis and AstraZeneca's Phase 3 ATTR-CM trial misses its primary goal, analyst says the outcome favors existing and next-gen therapies.
benzinga.com Aehr Test Systems, Lam Research, Applied Materials And Other Big Stocks Moving Higher On Thursday U.S. stocks higher, Nasdaq up 150+ points. Aehr Test Systems shares rose 13.6%. Other big gainers include FBRX, BBIO, TRAX, LASR, ONTO, ALNY, ICHR, LITE, ARM, LRCX, KLAC, and FORM.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 134.0% to $7.44 during Thursday's pre-market session. The company's market cap stands at $2.5 million. Alnylam Pharmaceuticals…
benzinga.com Why Ultra Clean Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket Stocks moving: RPGL +54.5%, EDBL +42.5%, SDOT +27.4%, BJDX +24.6%, AP +19.9%, SUNE +18%, ALNY +15.3%, AIBZ +14.3%, BBIO +10%. Losers: AFJK -25.8%, VTAK -19%, APVO -18%, NQ -16.3%.- benzinga.com BridgeBio Announces Publication Of New Analyses In Circulation: Heart Failure, Examining Kidney Function In Individuals With Transthyretin Amyloid Cardiomyopathy Treated With Acoramidis - Acoramidis initiation was associated with rapid kidney-protective activity as exhibited in a hemodynamically mediated, reversible eGFR dip and a placebo-corrected 15.5% reduction in UACR by Day 28…
- benzinga.com BridgeBio Pharma Agrees To Sell Up To $1B Of Convertible Preferred Stock To Sixth Street And KKR's HealthCare Royalty BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced
- benzinga.com Reported Sunday, BridgeBio PROPEL 3 Phase 3 Trial Published In NEJM, Oral Infigratinib Demonstrates Statistically Significant Improvements In Height, Body Proportionality In Achondroplasia - Phase 3 PROPEL 3 data published today in NEJM were simultaneously presented at ICCBH in a late-breaking oral presentation; presentation includes new arm span Z-score data showing a statistically…
- benzinga.com BridgeBio Pharma To Share Additional Data From PROPEL 3, Its Phase 3 Pivotal Study Of Oral Infigratinib In Children Living With Achondroplasia, In A Late Breaking Oral Presentation At The International Congress Of Children’s Bone Health, June 27-30 BridgeBio will also share an oral presentation and four posters at the meeting highlighting quality of life, early intervention research, observational study findings, and educational resources…
- benzinga.com Mizuho Maintains Outperform on BridgeBio Pharma, Lowers Price Target to $96 Mizuho analyst Salim Syed maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and lowers the price target from $106 to $96.
- benzinga.com Canaccord Genuity Initiates Coverage On BridgeBio Pharma with Buy Rating, Announces Price Target of $104 Canaccord Genuity analyst Whitney Ijem initiates coverage on BridgeBio Pharma (NASDAQ:BBIO) with a Buy rating and announces Price Target of $104.
- benzinga.com Morgan Stanley Maintains Overweight on BridgeBio Pharma, Raises Price Target to $98 Morgan Stanley analyst Sean Laaman maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $94 to $98.